A detailed history of Ifm Investors Pty LTD transactions in Catalent, Inc. stock. As of the latest transaction made, Ifm Investors Pty LTD holds 34,432 shares of CTLT stock, worth $2.19 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
34,432
Previous 35,543 3.13%
Holding current value
$2.19 Million
Previous $2 Million 4.35%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$56.16 - $60.96 $62,393 - $67,726
-1,111 Reduced 3.13%
34,432 $2.09 Million
Q1 2024

Apr 22, 2024

BUY
$42.56 - $59.82 $143,512 - $201,713
3,372 Added 10.48%
35,543 $2.01 Million
Q3 2023

Oct 26, 2023

BUY
$44.2 - $50.2 $119,340 - $135,540
2,700 Added 9.16%
32,171 $1.46 Million
Q2 2023

Jul 27, 2023

BUY
$31.86 - $67.26 $11,788 - $24,886
370 Added 1.27%
29,471 $1.28 Million
Q1 2023

May 11, 2023

BUY
$45.44 - $74.26 $67,705 - $110,647
1,490 Added 5.4%
29,101 $1.91 Million
Q2 2022

Jul 15, 2022

BUY
$87.2 - $114.05 $112,488 - $147,124
1,290 Added 4.9%
27,611 $2.96 Million
Q1 2022

Apr 13, 2022

BUY
$94.19 - $124.49 $373,369 - $493,478
3,964 Added 17.73%
26,321 $2.92 Million
Q3 2021

Oct 13, 2021

BUY
$109.17 - $142.35 $11,572 - $15,089
106 Added 0.48%
22,357 $2.98 Million
Q2 2021

Jul 16, 2021

BUY
$100.34 - $115.69 $536,116 - $618,131
5,343 Added 31.6%
22,251 $2.41 Million
Q1 2021

May 05, 2021

BUY
$101.51 - $125.27 $165,867 - $204,691
1,634 Added 10.7%
16,908 $1.78 Million
Q4 2020

Jan 13, 2021

BUY
$85.88 - $105.36 $232,047 - $284,682
2,702 Added 21.49%
15,274 $1.59 Million
Q3 2020

Oct 16, 2020

BUY
$72.74 - $92.5 $91,361 - $116,180
1,256 Added 11.1%
12,572 $1.08 Million
Q2 2020

Jul 13, 2020

BUY
$48.02 - $79.04 $543,394 - $894,416
11,316 New
11,316 $829,000

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Ifm Investors Pty LTD Portfolio

Follow Ifm Investors Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifm Investors Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Ifm Investors Pty LTD with notifications on news.